Nivolumab
Programmed Death Receptor-1 (PD-1) Blocking Antibody / Immune Checkpoint Inhibitor
Medicine brands for Nivolumab
Verified branded and generic formulations containing Nivolumab:
Nivolumab Uses
Doctors prescribe Nivolumab to treat a wide spectrum of advanced or metastatic cancers, including non-small cell lung cancer, skin cancer (melanoma), kidney cancer, liver cancer, esophageal cancer, and head and neck cancers. It can be used on its own, combined with targeted drugs like ipilimumab, or paired with standard chemotherapy depending on the cancer type and stage.
How Nivolumab works
Cancer cells often hide from your body's immune system by using specific chemical pathways to turn off T-cell defenses. Nivolumab is a targeted monoclonal antibody that binds to the PD-1 receptor on your T-cells. By blocking this signal, it essentially takes the brakes off your immune system, allowing your white blood cells to recognize, attack, and destroy cancer cells naturally.
Common side effects of Nivolumab
Most side effects do not require stopping therapy and improve as your body adjusts to the medicine. Consult your oncologist if any symptom worsens or persists.
Expert advice for Nivolumab
- •Received as a slow intravenous (IV) infusion into a vein at a hospital or specialized cancer clinic.
- •Pay close attention to how your body feels; report sudden chest tightness, shortness of breath, severe diarrhea, or skin yellowing right away because these can be early signs of immune system side effects.
- •Use reliable contraception while taking this medication and keep using it for at least 5 months after your last treatment.
- •Your medical team will run periodic blood tests to monitor your thyroid function, liver enzymes, and kidneys throughout your therapy.
- •Tell your doctor right away if you have any history of autoimmune conditions (like lupus or Crohn's) or organ transplants before starting treatment.
Safety advice for Nivolumab
Pregnancy
Unsafe. Nivolumab can cause the mother's immune system to attack the fetus, leading to severe pregnancy complications or loss.
Breastfeeding
Unsafe. Stop nursing during treatment and do not resume for at least 5 months after your final dose to avoid transferring antibodies to the baby.
Alcohol
Caution advised. While alcohol doesn't directly interfere with the drug's mechanism, it can worsen fatigue, dehydration, and liver strain during cancer therapy.
Driving
Generally safe. Avoid driving or operating machinery if you feel unusually exhausted or dizzy right after your infusion session.
Authoritative References & Citations
Clinical pharmacology and monographs verified against official drug regulatory authorities:
Editorial & Review Standards: Clinical information is verified by Nitin Kumar, D.Pharm (Diploma in Pharmacy) (UPPC Reg: 63405) in accordance with our Medical Review Policy. Educational only; not a substitute for professional oncological consultation.
Frequently Asked Questions about Nivolumab
Composition Summary
- Salt Name
- Nivolumab
- Drug Class
- Programmed Death Receptor-1 (PD-1) Blocking Antibody / Immune Checkpoint Inhibitor
- Storage
- Cold Chain (2°C–8°C)
- Prescription
- Required (Rx)
- Indication
- Lung Cancer
Oncology Pharmacy Support
Need help checking brand availability, batch certificates, or uploading a doctor prescription?
Sourced directly from licensed oncology pharmaceutical manufacturers with strict temperature controls and verifiable batch authenticity.